Remove tag non-adherence
article thumbnail

PharmaShots Weekly Snapshots (May 01 - 05, 2023)

PharmaShots

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Date: May 05, 2023 | Tags: Chiesi Global Rare Diseases, Protalix BioTherapeutics, PRX-102, pegunigalsidase alfa, Fabry Disease, Regulatory, EC, Marketing Authorization Kinoxis Therapeutics (..)

FDA 40
article thumbnail

Patient adherence – the key to restoring trust in pharma

pharmaphorum

This lack of trust in such a crucial industry can lead to decreased compliance, poor treatment adherence, and negative health outcomes for patients. This discrepancy can be caused by a variety of factors, however, one of the primary and most solvable ones is patient non-adherence to their medications.